These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

809 related articles for article (PubMed ID: 18398971)

  • 1. Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda.
    Buchacz K; Weidle PJ; Moore D; Were W; Mermin J; Downing R; Kigozi A; Borkowf CB; Ndazima V; Brooks JT
    J Acquir Immune Defic Syndr; 2008 Mar; 47(3):304-11. PubMed ID: 18398971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral treatment associated hyperglycemia and dyslipidemia among HIV infected patients at Burayu Health Center, Addis Ababa, Ethiopia: a cross-sectional comparative study.
    Abebe M; Kinde S; Belay G; Gebreegziabxier A; Challa F; Gebeyehu T; Nigussie P; Tegbaru B
    BMC Res Notes; 2014 Jun; 7():380. PubMed ID: 24950924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
    Anastos K; Lu D; Shi Q; Tien PC; Kaplan RC; Hessol NA; Cole S; Vigen C; Cohen M; Young M; Justman J
    J Acquir Immune Defic Syndr; 2007 May; 45(1):34-42. PubMed ID: 17460470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of HIV infection and HAART on serum lipids in men.
    Riddler SA; Smit E; Cole SR; Li R; Chmiel JS; Dobs A; Palella F; Visscher B; Evans R; Kingsley LA
    JAMA; 2003 Jun; 289(22):2978-82. PubMed ID: 12799406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study.
    Dai L; Liu A; Zhang H; Wu H; Zhang T; Su B; Shao Y; Li J; Ye J; Scott SR; Mahajan SD; Schwartz SA; Yu H; Sun L
    Curr HIV Res; 2019; 17(5):324-334. PubMed ID: 31654514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda.
    Forna F; Liechty CA; Solberg P; Asiimwe F; Were W; Mermin J; Behumbiize P; Tong T; Brooks JT; Weidle PJ
    J Acquir Immune Defic Syndr; 2007 Apr; 44(4):456-62. PubMed ID: 17279048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in Lipid Indices in HIV+ Cases on HAART.
    Ji S; Xu Y; Han D; Peng X; Lu X; Brockmeyer NH; Wu N
    Biomed Res Int; 2019; 2019():2870647. PubMed ID: 30868068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
    Kiage JN; Heimburger DC; Nyirenda CK; Wellons MF; Bagchi S; Chi BH; Koethe JR; Arnett DK; Kabagambe EK
    Lipids Health Dis; 2013 Apr; 12():50. PubMed ID: 23575345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dyslipidemia among HIV-infected Patients with tuberculosis taking once-daily nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in India.
    Padmapriyadarsini C; Ramesh Kumar S; Terrin N; Narendran G; Menon PA; Ramachandran G; Subramanyan S; Venkatesan P; Wanke C; Swaminathan S
    Clin Infect Dis; 2011 Feb; 52(4):540-6. PubMed ID: 21252141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naïve patients prescribed efavirenz compared to atazanavir/ritonavir.
    Gotti D; Cesana BM; Albini L; Calabresi A; Izzo I; Focà E; Motta D; Bellagamba R; Fezza R; Narciso P; Sighinolfi L; Maggi P; Brianese N; Quiros-Roldan E; Guaraldi G; Torti C
    HIV Clin Trials; 2012; 13(5):245-55. PubMed ID: 23134625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly active antiretroviral therapy and dyslipidemia in people living with HIV/AIDS in Fako Division, South West Region of Cameroon.
    Nsagha DS; Weledji EP; Assob NJ; Njunda LA; Tanue EA; Kibu OD; Ayima CW; Ngowe MN
    BMC Cardiovasc Disord; 2015 Aug; 15():95. PubMed ID: 26315756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir.
    Llibre JM; Domingo P; Palacios R; Santos J; Pérez-Elías MJ; Sánchez-de la Rosa R; Miralles C; Antela A; Moreno S;
    AIDS; 2006 Jun; 20(10):1407-14. PubMed ID: 16791015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy.
    Mankhatitham W; Luaengniyomkul A; Manosuthi W
    J Med Assoc Thai; 2012 Feb; 95(2):163-9. PubMed ID: 22435244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE).
    Shaffer D; Hughes MD; Sawe F; Bao Y; Moses A; Hogg E; Lockman S; Currier J
    J Acquir Immune Defic Syndr; 2014 Jun; 66(2):155-63. PubMed ID: 24562349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infection.
    Koppel K; Bratt G; Eriksson M; Sandström E
    Int J STD AIDS; 2000 Jul; 11(7):451-5. PubMed ID: 10919487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
    Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy.
    Riddler SA; Li X; Chu H; Kingsley LA; Dobs A; Evans R; Palella F; Visscher B; Chmiel JS; Sharrett A
    HIV Med; 2007 Jul; 8(5):280-7. PubMed ID: 17561873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study.
    Kamara DA; Smith C; Ryom L; Reiss P; Rickenbach M; Phillips A; Mocroft A; De Wit S; Law M; Monforte AD; Dabis F; Pradier C; Lundgren JD; Sabin C
    Antivir Ther; 2016; 21(6):495-506. PubMed ID: 27114439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid changes in Kenyan HIV-1-infected infants initiating highly active antiretroviral therapy by 1 year of age.
    Langat A; Benki-Nugent S; Wamalwa D; Tapia K; Ngugi E; Diener L; Richardson BA; Melvin A; John-Stewart GC
    Pediatr Infect Dis J; 2013 Jul; 32(7):e298-304. PubMed ID: 23385950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of dyslipidaemia among HIV-infected patients receiving combination antiretroviral therapy in North Shewa, Ethiopia.
    Fiseha T; Alemu W; Dereje H; Tamir Z; Gebreweld A
    PLoS One; 2021; 16(4):e0250328. PubMed ID: 33905435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.